Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PDK1 | Q15118 | 4/20 | 0.42 |
| ▸ | EPHA2 | P29317 | 4/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.36 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL731455 | 1.00 | USP2 (0.46) | USP2SMN1; SMN2PDK1EPHA2RECQL | |
| SCHEMBL1227594 | 1.00 | USP2 (0.46) | USP2SMN1; SMN2PDK1EPHA2RECQL | |
| SCHEMBL15416553 | 0.89 | USP2 (0.44) | USP2SMN1; SMN2PDK1EPHA2RECQL | |
| SCHEMBL20913831 | 0.88 | USP2 (0.43) | USP2SMN1; SMN2PDK1EPHA2RECQL | |
| SCHEMBL31712322 | 0.88 | USP2 (0.43) | USP2SMN1; SMN2PDK1EPHA2RECQL | |
| SCHEMBL19448268 | 0.86 | USP2 (0.43) | USP2SMN1; SMN2PDK1EPHA2RECQL | |
| SCHEMBL20913848 | 0.86 | USP2 (0.43) | USP2SMN1; SMN2PDK1EPHA2RECQL | |
| SCHEMBL20913869 | 0.85 | GPR119 (0.42) | USP2SMN1; SMN2EPHA2RECQLNR1H2 | |
| SCHEMBL18689807 | 0.85 | GPR119 (0.42) | USP2SMN1; SMN2EPHA2RECQLNR1H2 | |
| SCHEMBL8891747 | 0.85 | GPR119 (0.42) | USP2SMN1; SMN2EPHA2RECQLNR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12606550-B2 | Methods for synthesis of CHK1 inhibitors | CRT PIONEER FUND LP (GB) | 2026-04-21 | — | — | US | disclosed |
| US-12570672-B2 | Macrocyclic compounds and methods of use | AMGEN INC. | 2026-03-10 | — | — | US | disclosed |
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250304599-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-10-02 | — | — | US | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-4598921-A1 | MACROCYCLIC KRAS INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20250236631-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-07-24 | — | — | US | disclosed |
| EP-3731869-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-8865726-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors | ARRAY BIOPHARMA INC. (US) | 2014-10-21 | — | — | US | disclosed |
| WO-2014078454-A1 | BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | ARRAY BIOPHARMA INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| US-20120178715-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-07-12 | — | — | US | disclosed |
| WO-2011029027-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-03-10 | — | — | WO | disclosed |
| US-20090118288-A1 | N-Benzyl-Morpholine Derivatives as Modulators of the Chemokine Receptor | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| US-20090118288-A1 | N-Benzyl-Morpholine Derivatives as Modulators of the Chemokine Receptor | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| US-20090118288-A1 | N-Benzyl-Morpholine Derivatives as Modulators of the Chemokine Receptor | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| EP-1919884-A1 | N-BENZYL-MORPHOLINE DERIVATIVES AS MODULATORS OF THE CHEMOKINE RECEPTOR | AstraZeneca AB (SE) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007011292-A1 | N-BENZYL-MORPHOLINE DERIVATIVES AS MODULATORS OF THE CHEMOKINE RECEPTOR | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007011292-A1 | N-BENZYL-MORPHOLINE DERIVATIVES AS MODULATORS OF THE CHEMOKINE RECEPTOR | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545659-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK4 | USP2 740/4885SMN1; SMN2 1781/4885PDK1 590/4885 |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | USP2 141/4885SMN1; SMN2 2647/4885PDK1 504/4885 |
| US-20120178715-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MTOR, RICTOR, EIF4EBP1 | USP2 4444/4885SMN1; SMN2 2220/4885PDK1 271/4885 |
| US-20250236631-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | USP2 3635/4885SMN1; SMN2 3059/4885PDK1 705/4885 |
| US-12606550-B2 | Methods for synthesis of CHK1 inhibitors | CHEK1, CHEK2, RAD1 | USP2 1479/4885SMN1; SMN2 2164/4885PDK1 466/4885 |
| US-12570672-B2 | Macrocyclic compounds and methods of use | KRAS, NRAS, BRAF | USP2 3246/4885SMN1; SMN2 1780/4885PDK1 1342/4885 |
| US-20250304599-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | USP2 3635/4885SMN1; SMN2 3059/4885PDK1 705/4885 |
| US-20090118288-A1 | N-Benzyl-Morpholine Derivatives as Modulators of the Chemokine Receptor | CCR3, CCR1, CCR5 | USP2 4659/4885SMN1; SMN2 1725/4885PDK1 4707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.